Nigeria's Federal and State governments ratify new health reforms, lowering the voluntary HIV/AIDS testing age to 14 and ...

Stakeholders in Nigeria’s HIV response have renewed calls for sustainable domestic financing and more government–civil ...

The Department of Health said the decision reflects its mandate to ensure that all citizens have access to safe, effective, ...

Tennessee Gov. Bill Lee said the state had applied for a federal grant funding for rural healthcare, hoping for a piece of ...

Learn about the risk of getting HIV from anal sex, vaginal sex, oral sex, and shared needles, plus the most effective ways to ...

Gilead Sciences, Inc. is rated a Buy with robust profitability, solid dividend, prudent M&A and 15-20% upside potential. Read ...

Gilead's Phase 3 ARTISTRY-1 trial shows its single-tablet HIV regimen of bictegravir and lenacapavir matches the efficacy and safety of current therapy.

The Education Department has released its annual "Approved School Construction List,” with only two names on it: one is the ...

Lower middle- and low-income countries are less likely to receive market authorization for drugs that were trialed within their state and approved by the FDA within 5 years of approval when compared ...

Gilead Sciences, Inc. GILD announced that its investigational single-tablet regimen (STR) of bictegravir and lenacapavir for ...

Positive results mark an important step forward in efforts to develop effective treatments for children with drug-resistant TB COPENHAGEN, Denmark, Nov. 19, 2025 /PRNewswire/ -- New interim data from ...

Today, Seema Sahay is Head of Division of Social Behavioural Research at the Indian Council of Medical Research, National Institute of Translational Virology & AIDS Research (NARI), Pune, India.